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Open access under CC BYMutations of the gene for glucocerebrosidase 1 (GBA) cause Gaucher disease (GD), an autosomal recessive
lysosomal storage disorder. Individuals with homozygous or heterozygous (carrier) mutations of GBA have
a signiﬁcantly increased risk for the development of Parkinson’s disease (PD), with clinical and pathological
features that mirror the sporadic disease. The mechanisms whereby GBAmutations induce dopaminergic
cell death and Lewy body formation are unknown. There is evidence of mitochondrial dysfunction and oxi-
dative stress in PD and so we have investigated the impact of glucocerebrosidase (GCase) inhibition on
these parameters to determine if there may be a relationship of GBA loss-of-function mutations to the
known pathogenetic pathways in PD.We have used exposure to a speciﬁc inhibitor (conduritol-b-epoxide,
CbE) of GCase activity in a human dopaminergic cell line to identify the biochemical abnormalities that fol-
low GCase inhibition. We show that GCase inhibition leads to decreased ADP phosphorylation, reduced
mitochondrial membrane potential and increased free radical formation and damage, together with accu-
mulation of alpha-synuclein. Taken together, inhibition of GCase by CbE induces abnormalities in mito-
chondrial function and oxidative stress in our cell culture model. We suggest that GBA mutations and
reduced GCase activity may increase the risk for PD by inducing these same abnormalities in PD brain.
 2012 Elsevier Ltd. Open access under CC BY license.1. Introduction et al., 2009; Wong et al., 2004). There are now persuasive data thatGlucocerebrosidase 1 (GCase) is a ubiquitous lysosomal enzyme
responsible for the breakdown of glucocerebroside to glucose and
ceramide. Diverse mutations within the gene (GBA) that encodes
GCase result in mutant enzymes with reduced activity and an auto-
somal recessive storagedisorder (Gaucher disease–GD). GDpatients
have reduced GCase activity while heterozygote carriers generally
have an intermediate level (Raghavan et al., 1980). GD is character-
ised bywidespread accumulation of the GCase substrates glucocere-
broside or glucosylsphingosine in many organs (Grabowski, 2008).
Although GBA mutations cause a reduction in enzyme activity, this
may not necessarily be the mechanism that mediates the pathogen-
esis of GD and alternative models include mis-trafﬁcking of GCase
and endoplasmic reticulum stress (Kov-Bar et al., 2011).
Alpha-synuclein positive Lewy bodies have been identiﬁed in
the brains of GD patients and carriers who died with PD (NeumannClinical Neurosciences, UCL
3 2PF, United Kingdom. Tel.:
a).
.
 license.GBAmutations are a major risk factor for PD and result in a clinical
and pathological phenotype that is virtually indistinguishable from
sporadic PD (Sidransky et al., 2009).
The mechanism(s) whereby GBA mutations increase the risk for
PD remain unidentiﬁed. PD pathogenesis is thought to involve a
number of pathways including mitochondrial dysfunction and oxi-
dative stress (Schapira, 2006). Given the similar clinical and patho-
logical phenotypes of GBA–PD and sporadic PD, we hypothesised
that reduced GCase activity would result in biochemical events that
would map to these same pathways considered of pathological rel-
evance to familial and sporadic PD. We therefore investigated the
effects of a speciﬁc GCase inhibitor (conduritol-b-epoxide) on
mitochondrial function and free radical generation.2. Materials and methods
2.1. Reagents
Reagents were supplied by Sigma–Aldrich (Poole, UK) and
Merck (Nottingham, UK) unless otherwise stated.
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SHSY-5Y cells were maintained as described (Alvarez-Erviti
et al., 2010). During the course of continuous conduritol-b-epoxide
(CbE; Universal Biologicals, Cambridge, UK) treatment, cells were
split 1:3 every 3 days with fresh CbE added to a ﬁnal concentration
of 50 lM. GCase activity was monitored at different times through-
out the course of the experiment to check that inhibition was
maintained. Cell viability was checked by lactate dehydrogenase
(LDH) release assays (Roche, UK). In brief, cells were plated into
pairs of wells of a 48-well dish in phenol red-free media. After
48 h incubation of the control and CbE treatment, Triton X-100
was added to the medium of one of each pair of wells to a ﬁnal con-
centration of 1% and the LDH level in the medium served as its total
level. The LDH level found in the medium of the other well repre-
sents released LDH. Results were expressed as percentage LDH re-
lease from the total. For other assays, cells were harvested by
trypsinisation. If required for assay of GCase, mitochondrial respi-
ratory chain (MRC), or aconitase activities, cells were centrifuged at
1000 rpm, washed twice with phosphate-buffered saline (PBS) and
stored as a pellet at 80 C until assayed. Cells were then resus-
pended in 0.25 mM sucrose, 50 mM Tris (hydroxymethyl) amino-
methane hydrochloride (Tris–HCl) pH 7.4 and freeze–thawed
three times prior to assay. If required for adenosine diphosphate
(ADP) phosphorylation measurements, cell numbers were counted
using haemocytometers (Immune Systems; Paignton, UK), and
cells were centrifuged and resuspended in buffer for assays (see
below).2.3. Enzyme assays and ATP synthesis measurements
Respiratory chain (Schapira et al., 1990), proteasome (Schapira
et al., 2006), aconitase (Bradley et al., 2000) and ADP phosphoryla-
tion activities (Korlipara et al., 2004) were measured by standard
techniques as described previously. CbE-sensitive GCase activity
(end-point measurement) was determined at 37 C essentially as
described (Prence et al., 1996) using 4-Methylumbelliferyl-b-D-
glucopyranoside as substrate in a plate reader (‘Synergy’, LabTech;
Brighton, UK). The increase in ﬂuorescence of released 4-Methyl-
umbelliferone at 460 nm following excitation at 360 nm was
followed over 1 h. Protein levels were estimated using a bicinchon-
inic acid (BCA) kit (Pierce Thermo Fisher; Basingstoke, UK) with
reference to the protein standard supplied with the kit.2.4. Western blot analysis
Cells were harvested, washed with PBS and processed as de-
scribed (Alvarez-Erviti et al., 2010). 25–40 lg of whole cell lysates
were electrophoresed on Novex gels (NuPage 4–12%; Invitrogen,
Paisley, UK) and transferred onto polyvinylidene ﬂuoride mem-
brane (Millipore; Watford, UK) and then probed with antibodies
to porin (Merck; Darmstatd, Germany; 1/25000 dilution), adenine
nucleotide transporter (ANT; Abcam, UK, 1/1000 dilution), micro-
tubule-associated protein 1 light chain 3 (LC3, Clone D11; Cell Sig-
nalling, USA, 1/1000 dilution), alpha-synuclein (Becton–Dickinson,
UK, 1/500 dilution), Glucocerebrosidase (GBA; Abcam, UK, 1.1000
dilution) or lysosome-associated membrane proteins (lamp1, clone
H4A3; Abcam, UK, 1/1000 dilution) and all were normalised to
b-actin (Abcam; 1/5000 dilution) Blots were developed using an
enhanced chemiluminescence (ECL) kit (GE Healthcare; Little Chal-
font, UK), exposed to X-ray ﬁlm (GE Healthcare). The ﬁlm was
developed and signal intensities in the linear range were quantiﬁed
by the ‘Alphadigidoc’ software package (AlphaInnotech; San Lean-
dro, USA).2.5. Live cell confocal imaging and analysis
Fluorescence of cells grown on 22 mm coverslips were mea-
sured by real-time confocal imaging as described (Gandhi et al.,
2009; Duchen et al., 2003), using a Zeiss 510 laser scanning micro-
scope equipped with an additional Enterprise UV laser source and a
cooled charge coupled device camera, bathed in standard phenol
red-free Hank’s Buffered Salt Solution at room temperature. Mito-
chondrial membrane potential (Wm) was quantiﬁed by steady-
state ﬂuorescence (excited using the 543 nm laser line and mea-
sured using a 560 nm longpass ﬁlter) of mitochondrial patterns
produced by 25 nM tetramethyl rhodamine methyl ester (TMRM;
Invitrogen) stained at room temperature for 45 min. Free radical
generation was measured by the rate of ratiometric change of re-
duced and oxidised dihydroethidium (DHE; Invitrogen) ﬂuores-
cence. 10 lM of DHE was loaded at room temperature, and
measurements were made typically over 120 s. Oxidised DHE
was measured with the 543 nm laser line and 560 nm long-pass ﬁl-
ter, while for reduced DHE measurement it was excited at 351 and
measured at 435–485 nm. Cells were treated accordingly and mea-
sured at the same time to minimise variability of ﬂuorescence
measurements. Individual cells were marked and mean ﬂuores-
cence of individual cells measured by the ImageJ software (NIH,
USA); where the image was captured with Z-stack, z-projection
was performed using max intensity and net ﬂuorescence was ob-
tained by subtracting the background ﬂuorescence. Mitochondrial
morphology was measured on the circularity and aspect ratio from
the TMRM images by ImageJ as described (Wang et al., 2011).
2.6. Creation of GBA knockdown SHSY-5Y stable cell lines
SHSY-5Y cells were transfected with a ‘Hush’ GBA knockdown
plasmid (Origene, USA), empty plasmid and scrambled control
(The sequence chosen for the GBA knockdown was:
GTGTGTGTCTGCAATGCCACATACTGTGA). Stable clones were iso-
lated following selection with puromycin (Sigma, UK) at 4 lg/ml
and characterised by analysis of GCase activity, actin-normalised
GBA mRNA by a ‘StepOne’ QPCR machine (Applied Biosystems,
UK) using SyBr Green (Life Technologies, UK) and appropriate
primers for GBA and b-actin (Euroﬁns, Germany) and GCase protein
levels (by Western blotting). Clones were assessed after several
passages (in the presence of a maintenance dose of 2 lg/ml puro-
mycin) to check for the continuation of any knockdown effect.
2.7. Statistical analysis
Where multiple comparisons were made, one-way ANOVA tests
were performed followed by Dunnett post test analysis in order to
determine statistical signiﬁcance. Student’s t-tests were used for
comparing statistical signiﬁcance between 2 populations. A p value
of < 0.05 was considered as signiﬁcantly different.3. Results
3.1. CbE
CbE has been reported to be a selective inhibitor of GCase activ-
ity (Prence et al., 1996; Newburg et al., 1986) and we have con-
ﬁrmed in SHSY-5Y cells that 50 lM CbE decreased GCase activity
to 65% of untreated cells and maintained the inhibition of GCase
activity over 30 days (Suppl. Fig. 1). This concentration of CbE
has also been previously reported to result in a greater than 2-fold
increase of glucocerebroside over 24 days (Prence et al., 1996). In
our experiments, 30 days CbE treatment had no effect on cell via-
bility as judged by LDH release (Suppl. Fig. 2).
Fig. 1. CbE treatment led to a reduction in ADP phosphorylation. Glutamate
(complexes I, III and IV) and succinate-dependent (complexes II, III and IV) ADP
phosphorylation was signiﬁcantly impaired following incubation with CbE for
20 days onwards. Ascorbate/TMPD-dependent (complex IV) ADP phosphorylation
was not signiﬁcantly altered. Solid bars: control; diagonal line bars: 1 days
incubation; Dotted bars: 10 days incubation; horizontal striped bars: 20 days
incubation; open bars: 30 days incubation. Activities (mean ± SEM) were corrected
by cell number, measured from 3 experimental repeats. One-way ANOVA analysis
(followed by Dunnett post test) was performed on the data and showed that both
glutamate and succinate-linked activities were decreased signiﬁcantly from 20 days
onwards (⁄p < 0.05, ⁄⁄p < 0.01).
Table 1
Mitochondrial respiratory chain and proteasome activities following CbE treatment of
SHSY-5Y cells for 30 days.
Assay Control 30 days CbE
(a) MRC activities
CXI/CS  100 4.3 ± 1.1 3.3 ± 1
CXII/III/CS  1000 13.4 ± 0.6 14.6 ± 3.1
CXIV/CS  1000 4.3 ± 1.3 4.6 ± 0.8
(b) Proteasome activities*
PGP-like 1.6 ± 0.6 2.5 ± 0.25
Chymotrysin-like 6.0 ± 1.8 5.7 ± 2.0
Trypsin-like 8.7 ± 2.9 8.6 ± 1.4
* mFluorescence units/min/mg protein  106.
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3.2.1. ATP synthesis (ADP phosphorylation)
Fig. 1 shows the ADP phosphorylation capacity of digitonin-
permeabilised cells following incubation with CbE. There was no
measurable effect before 10 days, but complex I-linked ADP phos-
phorylation with glutamate/malate as substrate was signiﬁcantly
decreased by 47% at 20 days (p < 0.01) and by 33% at 30 days
(p < 0.05), compared to control. Complex II/III-linked ADP phos-
phorylation using succinate as substrate was signiﬁcantly reduced
by 30% at 20 days (p < 0.05) and 26% at 30 days (p < 0.05). There
was no signiﬁcant change in complex IV-linked ADP phosphoryla-
tion with ascorbate/TMPD as substrate. Basal levels of ATP (deter-
mined from time zero acid-treated samples) were 616 ± 149 and
643 ± 270 pmol/million cells, for control and 30 day treated cells
respectively. These values represented approximately 1.5–4.5% of
the values determined for ADP phosphorylation with glutamate/
malate over the incubation period.
3.2.2. Respiratory chain activities
There was no statistically signiﬁcant effect of CbE on the func-
tion of individual isolated respiratory chain complex enzymatic
activities (Table 1)
3.2.3. Mitochondrial membrane potential (Wm)
Fluorescence measurements of TMRM staining at nM level at its
steady-state produces mitochondrial staining patterns and they
are a reliable indicator of mitochondrial membrane potential in
live cells (Duchen et al., 2003). The sensitivity of the measurement
was validated by the complex I inhibitor rotenone, which reduced
Wm and TMRM ﬂuorescence, while the ATPase inhibitor oligomy-
cin increased Wm and TMRM ﬂuorescence (Fig. 2A).
There was no acute effect of CbE on TMRM staining and Wm
after 1 day, indicating there was no direct effect of the compound
on mitochondrial function or any quenching effect on ﬂuorescence
(Fig. 2A). CbE induced a progressive and signiﬁcant fall in Wm by20% at 10 days (p < 0.01), 23% at 20 days (p < 0.01) and 28% at
30 days (p < 0.01). We also observed fragmentation of the mito-
chondrial network at 30 days (Fig. 2B–D).
3.2.4. Mitochondrial content
Western blot analysis of the mitochondrial marker proteins por-
in and adenine nucleotide transporter (ANT), normalised to actin as
a loading control, showed no signiﬁcant change with CbE. This
indicates that CbE treatment for up to 30 days had no signiﬁcant
effect on mitochondrial content (Fig. 2E and F).
3.3. Oxidative stress
DHE ﬂuorescence was used to measure reactive oxygen species
generation in live cells, for example as demonstrated for the free
radical generator paraquat (Fig. 3A). CbE caused a signiﬁcant in-
crease in the rate of DHE oxidation by 52% at 20 days (p < 0.01)
and by 71% at 30 days (p < 0.01). Aconitase activity, a measure of
free radical mediated damage, was reduced by 60% (p < 0.001) after
30 days incubation with CbE (Fig. 3B).
3.4. Protein degradation studies
3.4.1. (A) Ubiquitin Proteasomal System (UPS)
The accumulation of alpha synuclein and other proteins in Lewy
bodies is a characteristic feature of PD pathology. The UPS has been
reported to be abnormal in PD brain and therefore potentially to
contribute to protein aggregation (McNaught and Jenner, 2001).
We investigated the effect of GCase inhibition on proteasomal
function, but found no abnormalities (Table 1). We did observe a
signiﬁcant increase (59%, p < 0.002) in alpha synuclein levels in
the treated cells, as determined by Western blotting (Fig. 4A and
B). Using alpha-synuclein fused to green ﬂuorescent protein
(GFP), at 20 days there was a 49% increase in levels as reﬂected
by ﬂuorescence in SHSY-5Y cells following CbE (Suppl. Fig. 3).
3.4.2. (B) Lysosomal studies
An indication that the lysosomal content of the cells was un-
changed is shown in Fig. 5A and B: Lamp1 levels (normalised to ac-
tin) showed no signiﬁcant difference between control cells and CbE
treated ones. Western blots of LC3-II on SHSY-5Y cells did not show
a change in the levels of LC3-II when GCase was inhibited by CbE
(Fig. 6A and B). Baﬁlomycin treatment (100 nM for 3 h) of these
cells did not appear to increase the observed levels signiﬁcantly).
3.5. GBA knockdown
To conﬁrm the effects of GCase inhibition by CbE, we generated a
stable shRNA-mediated knockdownmodel of GBA in SH-SY5Y cells.
Suppl. Fig. 4A shows that the enzyme activity was reduced by 62%
and Western blot band densities indicated that the level of protein
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Fig. 2. CbE treatment led to a progressive fall in mitochondria membrane potential (Wm) and no change in mitochondrial content. (A) Deﬂections in the system are
demonstrated by the use of rotenone (cross-hatched bar; ‘+rot’) and oligomycin (diagonal shaded bar; ‘+oligo’); ⁄⁄p < 0.001. Data (mean ± SEM) for each time point where 195
cells from 5 coverslips representing 3 independent preparations were analysed, and is expressed as percentage changes (open bars) to the untreated control (solid bar). 50 lM
CbE produced a signiﬁcant and progressive fall in Wm from 10 days (⁄p < 0.01 after ANOVA followed by Dunnett post test analysis). (B) Representative TMRM ﬂuorescence
images of untreated and SHSY-5Y cells treated with CbE for 30 days showing disruption of the mitochondrial network. (C) Image analysis reveals that both the circularity and
(D) aspect ratio of the mitochondria upon CbE treatment are signiﬁcantly increased (⁄p < 0.0001 by t-test), suggesting the mitochondria are more fragmented (solid bars:
control; open bars: treated cells. (E) Levels of porin and ANT were measured in SHSY-5Y cells incubated with 50 lM CbE for 30 days (lanes 4–6) by Western blot analysis,
against untreated cells (lanes 1–3) Blot (i) upper panel: b-actin; lower panel: ANT. Blot (ii) upper panel: b-actin; lower panel: porin. Graph (F) shows that there was no
signiﬁcant effect on porin or ANT levels (mean ± SEM, n = 3) by this treatment, (black bars, control; open bars: treated cells).
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scrambled control levels. Quantitative PCR data also showed a sig-
niﬁcant decrease of 60% in the mRNA for GBA relative to the scram-
bled control (data not shown). As shown in Suppl. Fig. 4D,
knockdown of GBA caused a signiﬁcant fall in TMRM ﬂuorescence
(p < 0.05) compared to the controls i.e. parental SHSY-5Y and cells
stably expressing the scrambled shRNA. There was a 38% reduction
(p = 0.003) in aconitase activity (Suppl. Fig. 4E). An increase in alpha
synuclein was seen in the knockdown cells, although this just failedto reach signiﬁcance (p < 0.067); Suppl. Fig. 5A and B). As seen with
the chemical model, the GCase knockdown cells did not show a sig-
niﬁcant increase in the basal LC3-II levels or when the cells were
treated with baﬁlomycin (100 nM, 3 h) (Suppl. Fig. 6A and B).
3.6. Other models of lysosomal inhibition
Inhibition of lysosomal function by baﬁlomycin or ammo-
nium chloride produced a different pattern of impaired ADP
Fig. 3. CbE treatment led to increased free radical production and reduced aconitase activity. (A) As a positive control, paraquat pre-treatment at 300 lM for 1 day (cross-
hatched bar; ‘+PQ’) signiﬁcantly increased the rate of DHE oxidation, as analysed by paired t-tests (p = 0.002). Continuous treatment of SHSY-5Y cells with 50 lM CbE (open
bars) showed a progressive increase in the rate of DHE oxidation after 20 days (⁄p < 0.01, mean percentage changes with respect to the untreated control (solid bar) ±SEM) as
determined by one-way ANOVA followed by Dunnett post test. (B) Aconitase activity was signiﬁcantly reduced (to 37% of control) after 30 days of CbE treatment
(mean ± SEM, ⁄⁄p < 0.001).
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treated cells). The level of alpha-synuclein protein was signiﬁcantly (⁄p < 0.002; n = 3) higher (by 59%) than that of control levels.
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ride) (Suppl. Fig. 7A). These inhibitors also showed different ef-
fects to CbE on mitochondrial membrane potential (Suppl.Fig. 7B). These results support our data that the mitochondrial
effects of CbE are not mediated directly through lysosomal
inhibition.
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Fig. 6. CbE treatment did not signiﬁcantly alter basal LC3-II levels. LC3-II levels were estimated for treated and control cells. CbE did not affect the basal levels of LC3-II. (A):
Shows Western blots of control and CbE cells (blot (i): without baﬁlomycin; blot (ii): with baﬁlomycin); control (lanes 1–3) or CbE (lanes 4–6). (B): Shows a graphical
representation of the result (solid bars: control, open bars: CbE treated). The levels did not change signiﬁcantly after CbE treatment.
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The aetiopathogenesis of PD is thought to involve an interaction
of genetic and environmental factors and includes mitochondrial
dysfunction, oxidative stress and protein handling abnormalities,
as well as inﬂammation (Schapira and Tolosa, 2010; Schapira,
2012). Speciﬁc gene mutations have been identiﬁed as causes of
familial PD and genome-wide association studies have highlighted
the importance of alpha-synuclein and tau as contributors to PD
risk. The genetic causes of familial PD are thought to initiate bio-
chemical events that map to these same pathways. GBA mutations
have now been reproducibly associated with a substantially in-
creased risk for PD estimated variously as 5 to 20-fold (Sidransky
et al., 2009; Bultron et al., 2010).
We have followed over time the effects of GCase enzyme inhi-
bition and knockdown on mitochondrial function and oxidative
stress. In our cell model, the ﬁrst change in function we observed
following CbE exposure was a progressive decline in mitochondrial
membrane potential that reached signiﬁcance at 10 days. Our
studies then showed that inhibition of GCase activity to a degree
comparable to that seen in GD (Raghavan et al., 1980), caused a sig-
niﬁcant reduction of ATP synthesis involving both complex I-linked
and complex II/III- linked ADP phosphorylation although the indi-
vidual respiratory chain protein activities were unaffected. This
deﬁciency was seen after 20 days incubation, suggesting that the
reduction in ATP synthesis was neither a direct result of CbE on
some cellular component, nor due to the immediate effects of
GCase inhibition but rather mediated via pathways resulting from
GCase inhibition. By 20 days there was also a signiﬁcant and pro-
gressive increase in free radical generation and this was main-
tained to 30 days, at which point there was also a signiﬁcant
reduction in aconitase activity, an indicator of free-radical medi-
ated damage. The fragmentation of mitochondria seen in cells ex-
posed to CbE corresponds with the fall in mitochondrial membrane
potential that is also observed on exposure to this toxin. It will be
of interest to investigate the function of mitophagy and mitochon-
drial biosynthesis in this model, and this is underway. It is possible
that the increased oxidative stress identiﬁed in this model may be
explained in part by an accumulation of defective mitochondria.
The UPS activities were not affected in our CbE model, but there
was evidence of accumulation of alpha-synuclein.
These results indicate that inhibition of a lysosomal enzyme,
GCase, causes abnormalities of mitochondrial function and oxida-tive stress, pathways that are also known to be defective in PD
brain. A defect of ATP synthesis but with normal individual respi-
ratory chain enzyme activities can be seen in certain mitochondrial
diseases and suggests a defect of electron transfer or mitochondrial
membrane defect (Schapira, 2012). Although CbE is considered a
speciﬁc inhibitor of GCase, we cannot completely exclude the pos-
sibility of off-target effects or secondary pathways initiated by
GCase inhibition inducing the effects seen. However, GBA knock-
down leading to a 62% reduction in enzyme activity induced a sim-
ilar pattern of changes with a decrease in mitochondrial membrane
potential and a signiﬁcant fall in aconitase activity. Furthermore,
the increase in oxidative stress observed here is compatible with
a previous observation from GD ﬁbroblast lines of an increase in
superoxide ions generated from non-phagocytic NADPH oxidase
and an associated increase in protein oxidation in the form of pro-
tein carbonyls (Deganuto et al., 2007).
Recent data have supported a role for defective lysosomal-
dependent degradation (autophagy) in PD. Abnormalities of the
chaperone-mediated autophagy (CMA) pathway have been dem-
onstrated in PD brain in anatomic regions that map to neuronal
degeneration and Lewy body deposition (Alvarez-Erviti et al.,
2010). GBA mutations would be expected to reduce GCase activity
in the lysosome and lead to the accumulation of glucocerebroside
and glucosylsphingosine. A direct interaction between GCase and
alpha-synuclein under lysosomal conditions has recently been de-
scribed (Yap et al., 2011). It is notable that GBA–PD pathology is al-
pha-synuclein Lewy body-positive, and alpha-synuclein is
predominantly metabolised by CMA. The accumulation of alpha
synuclein in GBA-associated PDmay therefore reﬂect reduced turn-
over secondary to impaired CMA or lysosomal function. Knock-
down of GCase has been shown to reduce the rate of proteolysis
in cells by 40% through disruption of the lysosomal pathway
(Mazzulli et al., 2011). Alpha synuclein steady state levels were in-
creased in GD cells and GCase knockout models with an accumula-
tion of a soluble high molecular weight form of the protein. Alpha
synuclein aggregates have also been seen in a mouse model of GD
(Sardi et al., 2011). It is of interest therefore that CbE inhibition of
GCase activity in our cell model caused an increase in alpha-synuc-
lein levels. This has also been reported following CbE treatment in
mouse substantia nigra (Manning-Bog et al., 2009). We have re-
cently studied post-mortem brain samples from PD patients with
and without GBAmutations (Gegg et al. in press). In addition to re-
duced GCase activity in both GBA positive and negative brains,
M.W.J. Cleeter et al. / Neurochemistry International 62 (2013) 1–7 7most profound in substantia nigra, we demonstrated in vivo and
in vitro features supportive of the reciprocal relationship between
alpha-synuclein and GCase activity. Thus, the lower the activity
of GCase, the higher the alpha-synuclein levels, and the greater
the expression of alpha-synuclein the lower the GCase activity.
The results from the present study indicate that inhibition of
GCase induces defects in mitochondrial function, increases oxida-
tive stress and conﬁrms previous reports that inhibition of this en-
zyme increases alpha-synuclein levels. These abnormalities are
also found in the PD brain, particularly in the substantia nigra,
the main site of neuronal degeneration. We suggest that GBAmuta-
tions and decreased GCase activity increase the risk for PD by
inducing or exacerbating these same abnormalities of mitochon-
drial function, oxidative stress and alpha-synuclein accumulation
to cause or accelerate the development of PD.
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